Look out, Bayer: Roche scores first global nod for targeted cancer drug Rozlytrek

As cancer treatment continues a march toward increasingly targeted therapies, Roche has secured its first global approval for Rozlytrek, a med designed to fight NTRK fusion-positive tumors and one that appears on a collision course with Bayer's Vitrakvi.